Epigenetic regulation of vitamin D 24-hydroxylase/CYP24A1 in human prostate cancer

Cancer Research

Volumn 70, Issue 14, 2010, Pages 5953-5962

  Luo, Wei ^a   Karpf, Adam R ^a   Deeb, Kristin K ^a   Muindi, Josephia R ^a   Morrison, Carl D ^a   Johnson, Candace S ^a   Trump, Donald L ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; BISULFITE; CALCITRIOL; CYTOCHROME P450; HISTONE DEACETYLASE; PROTEIN CYP 24 A 1; TRICHOSTATIN A; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DNA METHYLATION; DOWN REGULATION; EPIGENETICS; GENE EXPRESSION; HISTOLOGY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PYROSEQUENCING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

AZACITIDINE; CALCITRIOL; CELL LINE, TUMOR; DNA METHYLATION; DOWN-REGULATION; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; MALE; PROMOTER REGIONS, GENETIC; PROSTATIC NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; STEROID HYDROXYLASES;

EID: 77955037065     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-10-0617     Document Type: Article

References (47)

1. Haussler MR, Haussler CA, Jurutka PW, et al. The vitamin D hormone and its nuclear receptor: molecular actions and disease states. J Endocrinol 1997;154 Suppl:S57-73.
2. Holick MF. Vitamin D and bone health. J Nutr 1996;126:1159-64S.
3. DeLuca HF, Schnoes HK. Vitamin D: recent advances. Annu Rev Biochem 1983;52:411-39.
4. Pols HA, Birkenhager JC, Foekens JA, van Leeuwen JP. Vitamin D: a modulator of cell proliferation and differentiation. J Steroid Biochem Mol Biol 1990;37:873-6.
5. Chung I, Wong MK, Flynn G, Yu WD, Johnson CS, Trump DL. Differential antiproliferative effects of calcitriol on tumor-derived and Matrigel-derived endothelial cells. Cancer Res 2006;66: 8565-73. (Pubitemid 44449170)
6. Makin G, Lohnes D, Byford V, Ray R, Jones G. Target cell metabolism of 1,25-dihydroxyvitamin D3 to calcitroic acid. Evidence for a pathway in kidney and bone involving 24-oxidation. Biochem J 1989;262:173-80.
7. Beckman MJ, Tadikonda P, Werner E, Prahl J, Yamada S, DeLuca HF. Human 25-hydroxyvitamin D3-24-hydroxylase, a multicatalytic enzyme. Biochemistry 1996;35:8465-72. (Pubitemid 26240500)
8. Hosogane N, Shinki T, Kasuga H, Taketomi S, Toyama Y, Suda T. Mechanisms for the reduction of 24,25-dihydroxyvitamin D3 levels and bone mass in 24-hydroxylase transgenic rats. FASEB J 2003; 17:737-9.
9. Kasuga H, Hosogane N, Matsuoka K, et al. Characterization of transgenic rats constitutively expressing vitamin D-24-hydroxylase gene. Biochem Biophys Res Commun 2002;297:1332-8. (Pubitemid 35216393)
10. Masuda S, Byford V, Arabian A, et al. Altered pharmacokinetics of 1α,25-dihydroxyvitamin D3 and 25-hydroxyvitamin D3 in the blood and tissues of the 25-hydroxyvitamin D-24-hydroxylase (Cyp24a1) null mouse. Endocrinology 2005;146:825-34. (Pubitemid 40129840)
11. Masuda S, Strugnell SA, Knutson JC, St-Arnaud R, Jones G. Evidence for the activation of 1α-hydroxyvitamin D2 by 25-hydroxyvitamin D-24-hydroxylase: delineation of pathways involving 1α,24- dihydroxyvitamin D2 and 1α,25-dihydroxyvitamin D2. Biochim Biophys Acta 2006;1761:221-34.
12. Chung I, Karpf AR, Muindi JR, et al. Epigenetic silencing of CYP24 in tumor-derived endothelial cells contributes to selective growth inhibition by calcitriol. J Biol Chem 2007;282:8704-14. (Pubitemid 47093535)
13. Swami S, Krishnan AV, Peehl DM, Feldman D. Genistein potentiates the growth inhibitory effects of 1,25-dihydroxyvitamin D3 in DU145 human prostate cancer cells: role of the direct inhibition of CYP24 enzyme activity. Mol Cell Endocrinol 2005;241:49-61. (Pubitemid 41262171)
14. Yee SW, Campbell MJ, Simons C. Inhibition of vitamin D3 metabolism enhances VDR signalling in androgen-independent prostate cancer cells. J Steroid Biochem Mol Biol 2006;98:228-35. (Pubitemid 43344252)
15. Trump DL, Muindi J, Fakih M, Yu WD, Johnson CS. Vitamin D compounds: clinical development as cancer therapy and prevention agents. Anticancer Res 2006;26:2551-6. (Pubitemid 44155534)
16. Deeb KK, Trump DL, Johnson CS. Vitamin D signalling pathways in cancer: potential for anticancer therapeutics. Nat Rev Cancer 2007;7:684-700.
17. Anderson MG, Nakane M, Ruan X, Kroeger PE, Wu-Wong JR. Expression of VDR and CYP24A1 mRNA in human tumors. Cancer Chemother Pharmacol 2006;57:234-40. (Pubitemid 41779843)
18. Bareis P, Bises G, Bischof MG, Cross HS, Peterlik M. 25-Hydroxyvitamin D metabolism in human colon cancer cells during tumor progression. Biochem Biophys Res Commun 2001;285:1012-7.
19. Friedrich M, Rafi L, Mitschele T, Tilgen W, Schmidt W, Reichrath J. Analysis of the vitamin D system in cervical carcinomas, breast cancer and ovarian cancer. Recent Results Cancer Res 2003;164:239-46.
20. Parise RA, Egorin MJ, Kanterewicz B, et al. CYP24, the enzyme that catabolizes the antiproliferative agent vitamin D, is increased in lung cancer. Int J Cancer 2006;119:1819-28.
21. Mitschele T, Diesel B, Friedrich M, et al. Analysis of the vitamin D system in basal cell carcinomas (BCCs). Lab Invest 2004;84:693-702. (Pubitemid 38715470)
22. Reichrath J, Rafi L, Rech M, et al. Analysis of the vitamin D system in cutaneous squamous cell carcinomas. JCutan Pathol 2004;31:224-31.
23. Rhodes DR, Yu J, Shanker K, et al. ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia 2004;6:1-6.
24. Novakovic B, Sibson M, Ng HK, et al. Placenta-specific methylation of the vitamin D 24-hydroxylase gene: implications for feedback autoregulation of active vitamin D levels at the fetomaternal interface. J Biol Chem 2009;284:14838-48.
25. Ohyama Y, Kusada T, Yamasaki T, Ide H. Extensive methylation of CpG island of CYP24 gene in osteoblastic ROS17/2.8 cells. Nucleic Acids Res Suppl 2002;249-50.
26. Li LC, Dahiya R. MethPrimer: designing primers for methylation PCRs. Bioinformatics 2002;18:1427-31.
27. Chen KS, DeLuca HF. Cloning of the human 1α,25-dihydroxyvitamin D-3 24-hydroxylase gene promoter and identification of two vitamin D-responsive elements. Biochim Biophys Acta 1995;1263:1-9.
28. Tashiro K, Ishii C, Ryoji M. Role of distal upstream sequence in vitamin D-induced expression of human CYP24 gene. Biochem Biophys Res Commun 2007;358:259-65.
29. Woloszynska-Read A, James SR, Link PA, Yu J, Odunsi K, Karpf AR. DNA methylation-dependent regulation of BORIS/CTCFL expression in ovarian cancer. Cancer Immun 2007;7:21.
30. Väisänen S, Dunlop TW, Sinkkonen L, Frank C, Carlberg C. Spatiotemporal activation of chromatin on the human CYP24 gene promoter in the presence of 1α,25-dihydroxyvitamin D3. J Mol Biol 2005;350:65-77.
31. Milanesi L, D'Angelo D, Rogozin IB. GeneBuilder: interactive in silico prediction of gene structure. Bioinformatics 1999;15:612-21.
32. Zhang Y, Reinberg D. Transcription regulation by histone methylation: interplay between different covalent modifications of the core histone tails. Genes Dev 2001;15:2343-60.
33. Martin C, Zhang Y. The diverse functions of histone lysine methylation. Nat Rev Mol Cell Biol 2005;6:838-49.
34. Kondo Y, Shen L, Issa JP. Critical role of histone methylation in tumor suppressor gene silencing in colorectal cancer. Mol Cell Biol 2003;23:206-15.
35. Kawamoto K, Hirata H, Kikuno N, Tanaka Y, Nakagawa M, Dahiya R. DNA methylation and histone modifications cause silencing of Wnt antagonist gene in human renal cell carcinoma cell lines. Int J Cancer 2008;123:535-42.
36. Bakker J, Lin X, Nelson WG. Methyl-CpG binding domain protein 2 represses transcription from hypermethylated π-class glutathione S-transferase gene promoters in hepatocellular carcinoma cells. J Biol Chem 2002;277:22573-80.
37. Lopez-Serra L, Ballestar E, Fraga MF, Alaminos M, Setien F, Esteller M. A profile of methyl-CpG binding domain protein occupancy of hypermethylated promoter CpG islands of tumor suppressor genes in human cancer. Cancer Res 2006;66:8342-6.
38. Nan X, Ng HH, Johnson CA, et al. Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex. Nature 1998;393:386-9.
39. Jones PL, Veenstra GJ, Wade PA, et al. Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription. Nat Genet 1998; 19:187-91.
40. Khorchide M, Lechner D, Cross HS. Epigenetic regulation of vitamin D hydroxylase expression and activity in normal and malignant human prostate cells. J Steroid Biochem Mol Biol 2005;93:167-72.
41. Bachman KE, Park BH, Rhee I, et al. Histone modifications and silencing prior to DNA methylation of a tumor suppressor gene. Cancer Cell 2003;3:89-95.
42. Cedar H, Bergman Y. Linking DNA methylation and histone modification: patterns and paradigms. Nat Rev Genet 2009;10:295-304.
43. Jenuwein T, Allis CD. Translating the histone code. Science 2001; 293:1074-80.
44. Podvinec M, Kaufmann MR, Handschin C, Meyer UA. NUBIScan, an in silico approach for prediction of nuclear receptor response elements. Mol Endocrinol 2002;16:1269-79.
45. Schuster I, Egger H, Herzig G, et al. Selective inhibitors of vitamin D metabolism-new concepts and perspectives. Anticancer Res 2006; 26:2653-68.
46. Schuster I, Egger H, Astecker N, Herzig G, Schussler M, Vorisek G. Selective inhibitors of CYP24: mechanistic tools to explore vitamin D metabolism in human keratinocytes. Steroids 2001;66:451-62.
47. Chen TC. 25-Hydroxyvitamin D-1 α-hydroxylase (CYP27B1) is a new class of tumor suppressor in the prostate. Anticancer Res 2008;28:2015-7.